The ridiculously cheap Barratt share price and 8% yield are difficult to resist

Harvey Jones says house-builder Barratt Developments plc (LON: BDEV) looks like an income-hero-in-the-making.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

These are tough times for British house-builders, as a glance at the Barratt Developments (LSE: BDEV) share price will show you. Its stock surged in the boom years after the financial crisis, but is down 17% over the last 12 months, as sentiment towards bricks & mortar ebbs. However, the sell-off may have been overdone.

Ups and downs

There are certainly good reasons to be negative about property right now. Brexit. The slowing UK economy. Rising interest rates. The uncertain future of the Help to Buy scheme, which has driven demand for new-build properties.

Yet there are reasons to be positive, too. Barratt expects pre-tax profits to hit a record £835m, a rise of 9% on £765m in 2017, driven by its highest level of completions for a decade. It aims to boost new house sales by another 3-5% over coming years, while increasing its minimum margins from 20% to 23%. That’s being helped by new housing designs that are faster to build and reduce costs and waste.

Should you invest £1,000 in Crispr Therapeutics right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Crispr Therapeutics made the list?

See the 6 stocks

London falling

The weaker London market is a worry although the rest of the country is holding up, with average selling prices rising 5% to £288,000 last year. Investor concerns looked priced in, though, with Barrett trading at just 8.4 times earnings and offering a forecast yield of 7.9%, with cover of 1.5.

The risk you are taking is that interest rates rise faster than expected, or the property market slows, or we get a global financial crisis. In other words, the usual dangers when investing in stocks and shares. Barratt nonetheless has long-term recovery potential.

Moving on

This is a poor day for another property company, OnTheMarket (LSE: OTMP), which is down 5.45% at time of writing following publication of its interim results for the six months to 31 July.

The £79m group, which listed on AIM in February, was set up by estate agents to challenge the Rightmove and Zoopla “duopoly” and fight back against rising portal charges. Today, it posted a modest 1.4% rise in first-half revenues to £7m. But a 200% rise in administrative expenses to £12m left an adjusted operating loss of £5m, against a £2.9m profit last year. 

Listings up

Worryingly, average revenue per property advertiser fell from £194 to £153 over the period, but it wasn’t all gloom and doom. Period-end property listings jumped almost 74% to 7,788, while visits more than doubled to 69m.

Its cash position has also improved following its recent £30m fundraising to stand at £24.3m on 31 July, up from £3.26m six months earlier.

Power of three

Post-period end activity also shows promise, with OnTheMarket signing listing agreements with more than 11,000 estate agency and lettings branches, a 100% increase since admission to AIM. It also expanded its field sales team and launched a new national TV advertising campaign, driving visits and leads.

OnTheMarket has a battle on its hands, as it takes the fight to the big two. There are signs of progress, but admin and marketing expenses may rack up as it builds visibility in a slowing property market, with low transactions. My Foolish colleague Rupert Hargreaves is optimistic, though.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Crispr Therapeutics right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Crispr Therapeutics made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

harveyj has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Dividend Shares

How a stock market crash could boost investors’ passive income by over 40%

Jon Smith explains how a continued fall in the stock market isn't always a bad thing, especially when it comes…

Read more »

Investing Articles

If an investor put £10k into Greggs shares one month ago, here’s what they’d have today

Greggs shares have had a tough year but Harvey Jones says they're notably cheaper as a result, while the dividend…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

The Phoenix share price jumps 7.5% on today’s results, but still yields a stunning 9.4%!

Harvey Jones put his faith in the Phoenix share price and this morning was rewarded with a 7.5% jump on…

Read more »

Investing Articles

What’s been going on with the Barclays share price?

The rising Barclays share price reflects confidence in management’s strategy to improve business performance and enhance shareholder returns.

Read more »

Investing Articles

Prediction: in 1 year, the IAG share price could reach as high as…

The IAG share price has almost doubled in the last 12 months, but can this momentum continue in 2025? Zaven…

Read more »

Investing Articles

Prediction: in 12 months, here’s where the Glencore share price could be…

The performance of Glencore’s share price has been lacklustre, to say the least. But could all that change over the…

Read more »

Investing Articles

See how much an investor needs in their ISA to earn a £499 monthly second income

Harvey Jones crunches the numbers to show how it's possible to build a long-term second income by investing in a…

Read more »

Investing Articles

I’m considering buying more of this struggling FTSE 100 stock

This FTSE 100 stock hasn't exactly set our writer's portfolio on fire during the time he's owned it. But Paul…

Read more »